Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
Identifieur interne : 000615 ( Main/Corpus ); précédent : 000614; suivant : 000616Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
Auteurs : Elena Beyzarov ; Yan Chen ; Rob Julg ; Karen Naim ; Jigna Shah ; William W. Gregory ; Ayman Ayoub ; Patrick CaubelSource :
- Drug safety [ 1179-1942 ] ; 2021.
English descriptors
- KwdEn :
- Adverse Drug Reaction Reporting Systems (standards), Adverse Drug Reaction Reporting Systems (trends), Anticoagulants (adverse effects), Antimalarials (adverse effects), Antiviral Agents (adverse effects), COVID-19 (drug therapy), COVID-19 (epidemiology), Databases, Factual (standards), Databases, Factual (trends), Drug Industry (standards), Drug Industry (trends), Drug-Related Side Effects and Adverse Reactions (diagnosis), Drug-Related Side Effects and Adverse Reactions (epidemiology), Global Health (standards), Global Health (trends), Humans (MeSH), Immunosuppressive Agents (adverse effects), Pharmacovigilance (MeSH), Retrospective Studies (MeSH).
- MESH :
- chemical , adverse effects : Anticoagulants, Antimalarials, Antiviral Agents, Immunosuppressive Agents.
- diagnosis : Drug-Related Side Effects and Adverse Reactions.
- drug therapy : COVID-19.
- epidemiology : COVID-19, Drug-Related Side Effects and Adverse Reactions.
- standards : Adverse Drug Reaction Reporting Systems, Databases, Factual, Drug Industry, Global Health.
- trends : Adverse Drug Reaction Reporting Systems, Databases, Factual, Drug Industry, Global Health.
- Humans, Pharmacovigilance, Retrospective Studies.
Abstract
INTRODUCTION
Evidence-based clinical data on coronavirus disease 2019 (COVID-19) pharmacotherapies are scarce.
OBJECTIVE
This study documented and characterized COVID-19 cases reported in individuals receiving treatment with Pfizer pharmaceutical products and cases that reported use of Pfizer pharmaceutical products for COVID-19 treatment.
METHODS
This retrospective observational review leveraged the Pfizer safety database containing adverse event data collected in association with use of Pfizer products between 1 October, 2019, and 25 June, 2020; the database includes worldwide adverse event data from various sources. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA
RESULTS
Over 1500 relevant cases were identified over an 8-month period. In cases that reported COVID-19, immunosuppressant/immunomodulating agents, followed by anticoagulant/antithrombic agents and corticosteroids, were the most frequently reported agents. The frequent reporting of immunosuppressant/immunomodulating agents among cases of COVID-19 suggests increased vulnerability to infection among treated patients, either because of immunosuppressive effects of certain agents or the nature of the underlying treated condition. In cases involving off-label pharmacotherapy use for the treatment of COVID-19-related conditions, the most frequently reported therapeutic classes included antibiotics, antimalarial agents, antivirals/antiretroviral agents, immunosuppressant/immunomodulating agents, corticosteroids, anticoagulants, and immunoglobulin/interferons. The most frequently reported pharmacotherapeutic agents were azithromycin and chloroquine/hydroxychloroquine, followed by lopinavir-ritonavir, ceftriaxone, and tofacitinib. The most frequently reported clinical adverse events associated with azithromycin (as sole therapy or combined with chloroquine/hydroxychloroquine) include electrocardiogram QT prolonged, drug interaction, hepatitis, diarrhea, and hepatitis acute. Regarding cardiac-related events, 19% (120/645) of azithromycin cases reported events associated with QT prolongation/torsade de pointes (which included seven fatal cardiac events). The most frequently reported clinical adverse events associated with other commonly used agents are also presented.
CONCLUSIONS
This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.
DOI: 10.1007/s40264-020-01035-x
PubMed: 33354753
PubMed Central: PMC7755229
Links to Exploration step
pubmed:33354753Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.</title><author><name sortKey="Beyzarov, Elena" sort="Beyzarov, Elena" uniqKey="Beyzarov E" first="Elena" last="Beyzarov">Elena Beyzarov</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA. Elena.Beyzarov@pfizer.com.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Yan" sort="Chen, Yan" uniqKey="Chen Y" first="Yan" last="Chen">Yan Chen</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Julg, Rob" sort="Julg, Rob" uniqKey="Julg R" first="Rob" last="Julg">Rob Julg</name><affiliation><nlm:affiliation>Information Management Operations Center of Excellence, Global Product Development Pfizer Inc, Peapack, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Naim, Karen" sort="Naim, Karen" uniqKey="Naim K" first="Karen" last="Naim">Karen Naim</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shah, Jigna" sort="Shah, Jigna" uniqKey="Shah J" first="Jigna" last="Shah">Jigna Shah</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gregory, William W" sort="Gregory, William W" uniqKey="Gregory W" first="William W" last="Gregory">William W. Gregory</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ayoub, Ayman" sort="Ayoub, Ayman" uniqKey="Ayoub A" first="Ayman" last="Ayoub">Ayman Ayoub</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Caubel, Patrick" sort="Caubel, Patrick" uniqKey="Caubel P" first="Patrick" last="Caubel">Patrick Caubel</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33354753</idno><idno type="pmid">33354753</idno><idno type="doi">10.1007/s40264-020-01035-x</idno><idno type="pmc">PMC7755229</idno><idno type="wicri:Area/Main/Corpus">000615</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000615</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.</title><author><name sortKey="Beyzarov, Elena" sort="Beyzarov, Elena" uniqKey="Beyzarov E" first="Elena" last="Beyzarov">Elena Beyzarov</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA. Elena.Beyzarov@pfizer.com.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Yan" sort="Chen, Yan" uniqKey="Chen Y" first="Yan" last="Chen">Yan Chen</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Julg, Rob" sort="Julg, Rob" uniqKey="Julg R" first="Rob" last="Julg">Rob Julg</name><affiliation><nlm:affiliation>Information Management Operations Center of Excellence, Global Product Development Pfizer Inc, Peapack, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Naim, Karen" sort="Naim, Karen" uniqKey="Naim K" first="Karen" last="Naim">Karen Naim</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shah, Jigna" sort="Shah, Jigna" uniqKey="Shah J" first="Jigna" last="Shah">Jigna Shah</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gregory, William W" sort="Gregory, William W" uniqKey="Gregory W" first="William W" last="Gregory">William W. Gregory</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ayoub, Ayman" sort="Ayoub, Ayman" uniqKey="Ayoub A" first="Ayman" last="Ayoub">Ayman Ayoub</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Caubel, Patrick" sort="Caubel, Patrick" uniqKey="Caubel P" first="Patrick" last="Caubel">Patrick Caubel</name><affiliation><nlm:affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Drug safety</title><idno type="eISSN">1179-1942</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems (standards)</term><term>Adverse Drug Reaction Reporting Systems (trends)</term><term>Anticoagulants (adverse effects)</term><term>Antimalarials (adverse effects)</term><term>Antiviral Agents (adverse effects)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>Databases, Factual (standards)</term><term>Databases, Factual (trends)</term><term>Drug Industry (standards)</term><term>Drug Industry (trends)</term><term>Drug-Related Side Effects and Adverse Reactions (diagnosis)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Global Health (standards)</term><term>Global Health (trends)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Pharmacovigilance (MeSH)</term><term>Retrospective Studies (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term><term>Databases, Factual</term><term>Drug Industry</term><term>Global Health</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term><term>Databases, Factual</term><term>Drug Industry</term><term>Global Health</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pharmacovigilance</term><term>Retrospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Evidence-based clinical data on coronavirus disease 2019 (COVID-19) pharmacotherapies are scarce.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>This study documented and characterized COVID-19 cases reported in individuals receiving treatment with Pfizer pharmaceutical products and cases that reported use of Pfizer pharmaceutical products for COVID-19 treatment.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This retrospective observational review leveraged the Pfizer safety database containing adverse event data collected in association with use of Pfizer products between 1 October, 2019, and 25 June, 2020; the database includes worldwide adverse event data from various sources. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Over 1500 relevant cases were identified over an 8-month period. In cases that reported COVID-19, immunosuppressant/immunomodulating agents, followed by anticoagulant/antithrombic agents and corticosteroids, were the most frequently reported agents. The frequent reporting of immunosuppressant/immunomodulating agents among cases of COVID-19 suggests increased vulnerability to infection among treated patients, either because of immunosuppressive effects of certain agents or the nature of the underlying treated condition. In cases involving off-label pharmacotherapy use for the treatment of COVID-19-related conditions, the most frequently reported therapeutic classes included antibiotics, antimalarial agents, antivirals/antiretroviral agents, immunosuppressant/immunomodulating agents, corticosteroids, anticoagulants, and immunoglobulin/interferons. The most frequently reported pharmacotherapeutic agents were azithromycin and chloroquine/hydroxychloroquine, followed by lopinavir-ritonavir, ceftriaxone, and tofacitinib. The most frequently reported clinical adverse events associated with azithromycin (as sole therapy or combined with chloroquine/hydroxychloroquine) include electrocardiogram QT prolonged, drug interaction, hepatitis, diarrhea, and hepatitis acute. Regarding cardiac-related events, 19% (120/645) of azithromycin cases reported events associated with QT prolongation/torsade de pointes (which included seven fatal cardiac events). The most frequently reported clinical adverse events associated with other commonly used agents are also presented.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33354753</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.</ArticleTitle><Pagination><MedlinePgn>95-105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-020-01035-x</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Evidence-based clinical data on coronavirus disease 2019 (COVID-19) pharmacotherapies are scarce.</AbstractText><AbstractText Label="OBJECTIVE">This study documented and characterized COVID-19 cases reported in individuals receiving treatment with Pfizer pharmaceutical products and cases that reported use of Pfizer pharmaceutical products for COVID-19 treatment.</AbstractText><AbstractText Label="METHODS">This retrospective observational review leveraged the Pfizer safety database containing adverse event data collected in association with use of Pfizer products between 1 October, 2019, and 25 June, 2020; the database includes worldwide adverse event data from various sources. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA<sup>®</sup>) Preferred Terms and subsequent clinical review were used to characterize COVID-19 cases.</AbstractText><AbstractText Label="RESULTS">Over 1500 relevant cases were identified over an 8-month period. In cases that reported COVID-19, immunosuppressant/immunomodulating agents, followed by anticoagulant/antithrombic agents and corticosteroids, were the most frequently reported agents. The frequent reporting of immunosuppressant/immunomodulating agents among cases of COVID-19 suggests increased vulnerability to infection among treated patients, either because of immunosuppressive effects of certain agents or the nature of the underlying treated condition. In cases involving off-label pharmacotherapy use for the treatment of COVID-19-related conditions, the most frequently reported therapeutic classes included antibiotics, antimalarial agents, antivirals/antiretroviral agents, immunosuppressant/immunomodulating agents, corticosteroids, anticoagulants, and immunoglobulin/interferons. The most frequently reported pharmacotherapeutic agents were azithromycin and chloroquine/hydroxychloroquine, followed by lopinavir-ritonavir, ceftriaxone, and tofacitinib. The most frequently reported clinical adverse events associated with azithromycin (as sole therapy or combined with chloroquine/hydroxychloroquine) include electrocardiogram QT prolonged, drug interaction, hepatitis, diarrhea, and hepatitis acute. Regarding cardiac-related events, 19% (120/645) of azithromycin cases reported events associated with QT prolongation/torsade de pointes (which included seven fatal cardiac events). The most frequently reported clinical adverse events associated with other commonly used agents are also presented.</AbstractText><AbstractText Label="CONCLUSIONS">This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyzarov</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6190-9432</Identifier><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA. Elena.Beyzarov@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julg</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Information Management Operations Center of Excellence, Global Product Development Pfizer Inc, Peapack, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naim</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jigna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoub</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caubel</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Worldwide Research and Development, Pfizer Inc, 100 US-206, Peapack, NJ, 07977, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Drug Saf. 2021 Apr;44(4):399-402</RefSource><PMID Version="1">33666902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33354753</ArticleId><ArticleId IdType="doi">10.1007/s40264-020-01035-x</ArticleId><ArticleId IdType="pii">10.1007/s40264-020-01035-x</ArticleId><ArticleId IdType="pmc">PMC7755229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2021 Feb 25;384(8):693-704</Citation><ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Arthritis Rheum. 2020 Aug;50(4):680-686</Citation><ArticleIdList><ArticleId IdType="pubmed">32512263</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Jul - Aug;36:101791</Citation><ArticleIdList><ArticleId IdType="pubmed">32593867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 Jun;18(6):1320-1323</Citation><ArticleIdList><ArticleId IdType="pubmed">32329231</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2020 Jul;20(7):1911-1915</Citation><ArticleIdList><ArticleId IdType="pubmed">32315122</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2021 Jan;27(1):19-27</Citation><ArticleIdList><ArticleId IdType="pubmed">32860962</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2020 Jul;20(7):1864-1868</Citation><ArticleIdList><ArticleId IdType="pubmed">32277555</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Cardiol Rep. 2020 Apr 21;22(5):32</Citation><ArticleIdList><ArticleId IdType="pubmed">32318865</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflamm Bowel Dis. 2020 Jun 18;26(7):e64</Citation><ArticleIdList><ArticleId IdType="pubmed">32342098</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jul 2;383(1):85-88</Citation><ArticleIdList><ArticleId IdType="pubmed">32348641</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2021 Jan 11;21(1):47</Citation><ArticleIdList><ArticleId IdType="pubmed">33430799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Oct 3;396(10256):959-967</Citation><ArticleIdList><ArticleId IdType="pubmed">32896292</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):831-840</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Oct;56(4):106143</Citation><ArticleIdList><ArticleId IdType="pubmed">32853672</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000615 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000615 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33354753
|texte= Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33354753" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |